Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.62 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.62 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386868 | 0.94 | OPRD1 (0.82) | OPRD1OPRM1OPRK1NTSR1 | |
| SCHEMBL31197421 | 0.91 | OPRD1 (0.77) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL28101268 | 0.91 | OPRD1 (0.66) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL14889478 | 0.91 | OPRD1 (0.66) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL14889477 | 0.91 | OPRD1 (0.66) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL29648931 | 0.89 | OPRD1 (0.90) | OPRD1OPRM1OPRK1NTSR1 | |
| Dynorphin A (1-11) SCHEMBL30132402 | 0.89 | OPRD1 (0.86) | OPRD1OPRM1OPRK1NTSR1 | |
| Analog Of Dynorphin A SCHEMBL29389694 | 0.89 | OPRD1 (0.86) | OPRD1OPRM1OPRK1NTSR1 | |
| SCHEMBL31009049 | 0.89 | OPRD1 (0.88) | OPRD1OPRM1OPRK1NTSR1 | |
| SCHEMBL29878209 | 0.88 | OPRD1 (0.85) | OPRD1OPRM1OPRK1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3621632-B1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-08-22 | — | — | US | disclosed |
| US-20240263161-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | UNIVERSITY OF COPENHAGEN (DK) | 2024-08-08 | — | — | US | disclosed |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4347624-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | University of Copenhagen (DK) | 2024-04-10 | — | — | EP | disclosed |
| CN-109312335-B | Chimeric proteins and methods of modulating gene expression | 斯坦福大学托管董事会 | 2023-10-24 | — | — | CN | disclosed |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2023-07-20 | — | — | US | disclosed |
| EP-4168116-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | Biohaven Therapeutics Ltd. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115836052-A | Topical formulations of (1S) -1-phenyl-2-pyridin-2-ylethylamine | 拜尔哈文制药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2022253998-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | UNIVERSITY OF COPENHAGEN (DK) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | VIP, HAMP, HM13 | OPRD1 96/4885OPRM1 1215/4885OPRK1 703/4885 |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | VIP, NGLY1, SPPL2B | OPRD1 1049/4885OPRM1 3306/4885OPRK1 3025/4885 |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | OPRD1 1049/4885OPRM1 3306/4885OPRK1 3025/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | OPRD1 2320/4885OPRM1 1894/4885OPRK1 2852/4885 |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | OPRD1 1049/4885OPRM1 3306/4885OPRK1 3025/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | OPRD1 501/4885OPRM1 674/4885OPRK1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.